Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 17/20 | 0.47 |
| ▸ | CASP8 | Q14790 | 11/20 | 0.45 |
| ▸ | CASP1 | P29466 | 7/20 | 0.45 |
| ▸ | CASP7 | P55210 | 7/20 | 0.45 |
| ▸ | CASP6 | P55212 | 3/20 | 0.42 |
| ▸ | CASP9 | P55211 | 1/20 | 0.42 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 1/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5969948 | 0.86 | CASP3 (0.47) | CASP3CASP8CASP1CASP7CASP6 | |
| SCHEMBL5970032 | 0.85 | MCL1 (0.42) | CASP1MCL1ESR1ESR2 | |
| SCHEMBL8608833 | 0.85 | CASP3 (0.44) | CASP3CASP8CASP1CASP7CASP6 | |
| SCHEMBL5970715 | 0.84 | GAA (0.50) | CASP3CASP8CASP1CASP7CASP6 | |
| SCHEMBL8606968 | 0.78 | CASP3 (0.41) | CASP3CASP8CASP1CASP7CASP6 | |
| SCHEMBL5970017 | 0.77 | CASP3 (0.42) | CASP3CASP8CASP1CASP7CASP6 | |
| SCHEMBL5667954 | 0.75 | CASP3 (0.47) | CASP3CASP8CASP1CASP7CASP6 | |
| SCHEMBL2023877 | 0.73 | CASP3 (0.53) | CASP3CASP8CASP1CASP7CASP6 | |
| SCHEMBL2023872 | 0.73 | CASP3 (0.53) | CASP3CASP8CASP1CASP7CASP6 | |
| SCHEMBL5970102 | 0.73 | CASP3 (0.43) | CASP3CASP8CASP1CASP7CASP6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0929311-B8 | INHIBITION OF APOPTOSIS USING INTERLEUKIN-1 beta-CONVERTING ENZYME (ICE)/CED-3 FAMILY INHIBITORS | IDUN PHARMACEUTICALS INC (US) | 2006-02-01 | — | — | EP | disclosed |
| EP-1443935-A2 | TREATMENT OF INFECTIOUS DISEASE USING INTERLEUKIN-1 BETA CONVERTING ENZYME (ICE)/CED-3 FAMILY INHIBITORS | Idun Pharmaceuticals, Inc. (US) | 2004-08-11 | — | — | EP | disclosed |
| WO-2003032918-A2 | TREATMENT OF INFECTIOUS DISEASE USING INTERLEUKIN-1 BETA CONVERTING ENZYME (ICE)/CED-3 FAMILY INHIBITORS | IDUN PHARMACEUTICALS, INC. (US) | 2003-04-24 | — | — | WO | disclosed |
| WO-2002070544-A2 | METHODS, COMPOSITIONS AND KITS FOR PRESERVING ANTIGENICITY | IDUN PHARMACEUTICALS, INC. (US) | 2002-09-12 | — | — | WO | disclosed |
| EP-1159291-A1 | C-TERMINAL MODIFIED (N-SUBSTITUTED)-2-INDOLYLCARBONYLDIPEPTIDES AS INHIBITORS OF THE ICE/CED-3 FAMILY OF CYSTEINE PROTEASES | Idun Pharmaceuticals, Inc. (US) | 2001-12-05 | — | — | EP | disclosed |
| EP-0929311-A4 | INHIBITION OF APOPTOSIS USING INTERLEUKIN-1 beta-CONVERTING ENZYME (ICE)/CED-3 FAMILY INHIBITORS | IDUN PHARMACEUTICALS INC (US) | 2001-08-29 | — | — | EP | disclosed |
| WO-2001000658-A1 | C-TERMINAL MODIFIED (N-SUBSTITUTED)-2-INDOLYLCARBONYLDIPEPTIDES AS INHIBITORS OF THE ICE/CED-3 FAMILY OF CYSTEINE PROTEASES | IDUN PHARMACEUTICALS, INC. (US) | 2001-01-04 | — | — | WO | disclosed |
| EP-0929311-A1 | INHIBITION OF APOPTOSIS USING INTERLEUKIN-1 beta-CONVERTING ENZYME (ICE)/CED-3 FAMILY INHIBITORS | Idun Pharmaceuticals, Inc. (US) | 1999-07-21 | — | — | EP | disclosed |
| WO-1998010778-A1 | INHIBITION OF APOPTOSIS USING INTERLEUKIN-1β-CONVERTING ENZYME (ICE)/CED-3 FAMILY INHIBITORS | IDUN PHARMACEUTICALS, INC. (US) | 1998-03-19 | — | — | WO | disclosed |